Status:
COMPLETED
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The purpose of ...
Detailed Description
Buprenorphine, a mixed agonist-antagonist opioid (or partial agonist), is a safe and effective treatment for opioid dependence. However, there is concern that buprenorphine may be abused due to its hi...
Eligibility Criteria
Inclusion
- Currently opioid dependent
- In good health, as determined by a pre-participation medical examination
- Seeking and eligible for methadone maintenance or detoxification treatment
Exclusion
- Significant medical or psychiatric illness, other than drug dependence
Key Trial Info
Start Date :
August 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 1998
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00134914
Start Date
August 1 1996
End Date
May 1 1998
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University (BPRU) Bayview Campus
Baltimore, Maryland, United States, 21224 6823